Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants

doi:10.3748/wjg.v21.i4.1222

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 4

This Article

(322)

(440)

(0)

(6631)

(6)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Gastroenterol. Jan 28, 2015; 21(4): 1222-1233
Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1222

Table 2 Postoperative adjuvant treatment protocols n (%)

Treatment	Follow up (yr)		Total (n = 201)	P value¹
Treatment	Before 2008 (n = 127)	2008-2010 (n = 74)		P value¹
Chemoradiotherapy	84 (66.1)	63 (85.1)	Total (n = 201)	147 (73.1)	0.023
Chemotherapy	19 (15.0)	6 (8.1)	25 (12.4)
Supportive treatment	10 (7.9)	2 (2.7)	12 (6.0)
None (follow up)	14 (11.0)	3 (4.1)	17 (8.5)
Radiotherapy				0.003
No	43 (33.9)	11 (14.9)	54 (26.9)
Yes	84 (66.1)	63 (85.1)	147 (73.1)
Chemotherapy protocol				< 0.001
FUFA	70 (55.1)	42 (56.8)	112 (55.7)
CEF	9 (7.1)	21 (28.3)	30 (14.9)
None	14 (11.0)	3 (4.1)	17 (8.5)
UFT	23 (18.1)	1 (1.4)	24 (11.9)
TCF	1 (0.8)	5 (6.8)	6 (3.0)
Supportive	10 (7.9)	2 (2.7)	12 (6.0)
Type of radiotherapy device				< 0.001
Co60	21 (25.3)	0 (0.0)	21 (14.4)
Linak	58 (69.9)	7 (11.1)	65 (44.5)
Varian-Siemens	4 (4.8)	56 (88.9)	60 (41.1)
Simulator planning				< 0.001
2 dimensional	79 (62.7)	7 (9.5)	86 (43.0)
3 dimensional	4 (3.2)	56 (75.7)	60 (30.0)
No radiotherapy	43 (34.1)	11 (14.9)	54 (27.0)

¹χ² test. FUFA: 5-fluorouracil and leucovorin-folinic acid; CEF: Cyclophosphamide, epirubicin, and fluorouracil; UFT: Uracil/tegafur; TCF: Docetaxel, cisplatin, and fluorouracil.

Full Size Table

Citation: Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol 2015; 21(4): 1222-1233
URL: https://www.wjgnet.com/1007-9327/full/v21/i4/1222.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i4.1222

Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol 2015; 21(4): 1222-1233 [PMID: 25632196 DOI: 10.3748/wjg.v21.i4.1222]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.